Alliancebernstein L.P. Has $149.44 Million Stake in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)

Alliancebernstein L.P. cut its stake in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) by 23.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,075,834 shares of the company’s stock after selling 324,086 shares during the period. Alliancebernstein L.P. owned approximately 1.65% of Biohaven Pharmaceutical worth $149,444,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BHVN. Marshall Wace LLP bought a new stake in Biohaven Pharmaceutical during the 1st quarter worth $365,000. Advisor Group Holdings Inc. lifted its stake in shares of Biohaven Pharmaceutical by 6.4% in the 2nd quarter. Advisor Group Holdings Inc. now owns 2,275 shares of the company’s stock valued at $221,000 after purchasing an additional 137 shares during the period. Envestnet Asset Management Inc. lifted its stake in shares of Biohaven Pharmaceutical by 8.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,763 shares of the company’s stock valued at $365,000 after purchasing an additional 294 shares during the period. Sei Investments Co. lifted its stake in shares of Biohaven Pharmaceutical by 4.0% in the 2nd quarter. Sei Investments Co. now owns 12,477 shares of the company’s stock valued at $1,215,000 after purchasing an additional 477 shares during the period. Finally, State Board of Administration of Florida Retirement System lifted its stake in shares of Biohaven Pharmaceutical by 7.8% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 20,932 shares of the company’s stock valued at $2,032,000 after purchasing an additional 1,513 shares during the period. 89.17% of the stock is owned by hedge funds and other institutional investors.

BHVN stock opened at $122.17 on Friday. The business has a 50 day moving average of $120.73 and a 200-day moving average of $125.64. Biohaven Pharmaceutical Holding Company Ltd. has a 12-month low of $62.57 and a 12-month high of $151.51.

Biohaven Pharmaceutical (NYSE:BHVN) last released its earnings results on Monday, November 8th. The company reported ($2.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.23). The firm had revenue of $135.74 million during the quarter, compared to the consensus estimate of $128.40 million. The firm’s quarterly revenue was up 668.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.27) earnings per share. Analysts anticipate that Biohaven Pharmaceutical Holding Company Ltd. will post -12.18 earnings per share for the current fiscal year.

A number of research analysts have recently issued reports on the company. Piper Sandler boosted their price objective on Biohaven Pharmaceutical from $140.00 to $156.00 and gave the company an “overweight” rating in a research note on Tuesday, October 5th. SVB Leerink reissued a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Thursday, October 7th. UBS Group upped their price target on Biohaven Pharmaceutical from $150.00 to $160.00 in a research note on Tuesday, January 4th. Morgan Stanley upped their price target on Biohaven Pharmaceutical from $145.00 to $148.00 and gave the stock an “equal weight” rating in a research note on Friday, January 7th. Finally, Mizuho upped their price target on Biohaven Pharmaceutical from $135.00 to $144.00 and gave the stock a “buy” rating in a research note on Thursday, November 18th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $147.55.

In related news, Director Declan Doogan sold 37,740 shares of the stock in a transaction on Tuesday, November 16th. The stock was sold at an average price of $116.65, for a total value of $4,402,371.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Julia P. Gregory sold 12,000 shares of the stock in a transaction on Monday, December 20th. The shares were sold at an average price of $125.00, for a total value of $1,500,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 133,099 shares of company stock worth $14,807,430. Company insiders own 15.20% of the company’s stock.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators.

Further Reading: What is Depreciation?

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.